By James Lyons-Weiler, PhD
Popular Rationalism | September 2, 2026
Science located no antivaccine program in the Interagency Autism Coordinating Committee’s new strategic plan, so Sara Reardon’s August 31 article supplied one by inference. “In autism advisory committee’s funding plan, critics see a veiled antivaccine focus” acknowledges that the plan never mentions vaccines, then asks readers to treat its attention to regression, environmental exposures, immune biology, and committee members’ affiliations as evidence of what the document supposedly conceals. Alison Singer of the Autism Science Foundation states the method plainly: “We could read between the lines.”
That is a revealing sentence because the lines themselves do not establish the headline. A claim that a federal plan contains a veiled agenda requires evidence of how the veil operates. One would expect to find a vaccine exposure category, a funded vaccine protocol, an agency deliverable, a causal presumption, a surveillance variable, an endpoint, or at least language broad enough to direct investigators toward vaccination as the favored explanation. Reardon instead identifies Robert F. Kennedy Jr.’s views, the backgrounds of public committee members, and the personal beliefs of some parents on the committee. Those facts can justify scrutiny of the committee, but they cannot do the evidentiary work of showing what the plan directs the federal government to study.
The article then weakens its own insinuation. The researchers Reardon quotes agree that regression is real, poorly understood, and scientifically worth studying. Sally Ozonoff tells Science that prospective observation should replace dependence on parental memory, which is also what the IACC plan says before specifying how to do it. The paper Science links to support its account of timing says that developmental declines emerge around the first birthday and continue through the second year, yet Reardon tells readers that measurable declines occur primarily within the first 12 months and therefore before most routine vaccination. Her linked paper contradicts the first assertion, and the federal childhood immunization schedule contradicts the second, leaving the article in possession of the evidence needed to test its framing but unwilling to apply it.
The operative text points elsewhere
The official record requires one preliminary distinction. As of September 1, the IACC’s August 27 meeting page contains a 336-page August 17 updated working draft, proposed revisions, federal-member correction requests, and amendment documents. It does not yet provide a clean, consolidated post-vote edition. Any serious analysis should therefore identify which version it reviewed and avoid pretending that a working draft, an amendment packet, and a final integrated plan are interchangeable. The analysis here uses the August 17 updated working draft and notes the separate revision record where relevant.
A full-text search of that draft returns no occurrence of vaccine, vaccination, immunization, antigen, adjuvant, thimerosal, mercury, or aluminum. Absence of a word cannot prove the absence of every private intention, but a public funding plan is judged by its operative language. The relevant question is what the plan authorizes, recommends, measures, and funds. On those points the alleged vaccine focus never appears.
The plan instead adopts a heterogeneous model of autism. It states that autism arises through “multiple interacting developmental pathways” involving varying combinations of genetic susceptibility, biological vulnerability, environmental influence, and developmental timing. It warns against a single cause and says regression itself should not be treated as a single subtype or mechanism. Its environmental priorities are named: air pollution, pesticides, metals, endocrine-active chemicals, water contaminants, maternal health, placental biology, infection, medication, diet, nutrition, acute inflammatory or metabolic stressors, and cumulative mixtures. A reporter who believes vaccination is encoded somewhere in that list must identify the textual hook and explain why the listed exposures should be read as decoys, a showing Reardon never makes.
The budget is equally resistant to the headline. The draft’s FY2028 table recommends a total federal autism portfolio of $747.444 million. The dedicated National Neurodevelopmental Regression Initiative receives $57 million, with another $10 million regression domain inside the broader Part IV portfolio. Even on the draft’s maximal budget presentation, the two explicit regression lines total $67 million, just under nine percent of the recommended portfolio. The remaining plan covers neural circuits, immune and inflammatory biology, folate metabolism, gastrointestinal and microbiome biology, mitochondrial and metabolic function, autonomic dysfunction, sleep, epilepsy, motor planning, adaptive trials, diagnosis, communication, mental health, education, housing, caregivers, employment, aging, and transportation. Calling this a veiled vaccine funding plan requires the reader to disregard almost the entire allocation.
Reardon also invokes committee members who promote leucovorin, which invites readers to carry those members’ clinical views into the plan. The plan’s own language blocks that transfer on page 91: “This Plan does not recommend leucovorin as a treatment for autism.” It keeps FOLR1-related cerebral folate transport deficiency, other causes of cerebral folate deficiency, and an unconfirmed folate-receptor-alpha-autoantibody subgroup analytically separate. It calls for assay harmonization and an adequately powered multisite confirmatory trial before autism-wide clinical guidance or coverage. That distinction matches the FDA’s March 10, 2026 approval, which applies to patients with a confirmed FOLR1 variant, not to autism as a diagnosis. The section may be debated on its scientific merits, but describing committee members’ practices does not erase what the plan actually says.
Science’s own experts supply the rationale for studying regression
Reardon quotes UCLA psychologist Catherine Lord saying that regression is real, heartbreaking, and poorly understood, with little evidence that current interventions prevent or reverse it. She also reports that Ozonoff welcomes research attention to the subject while insisting on prospective follow-up from early life. Those statements are a rationale for the research initiative, not evidence against it. A clinically consequential event that affects a substantial minority of autistic children, lacks a standard definition, and has almost no established neurobiology is a defensible target for coordinated research.
The broader literature makes the case more concrete. A 2021 systematic review and meta-analysis by Christine Tan and colleagues included 97 studies, with 75 studies and 33,014 participants contributing to the meta-analysis. It estimated a pooled regression prevalence of 30 percent, although heterogeneity was extremely high, and found a weighted mean age of onset of 19.8 months. The authors called for a standardized definition and repeated measurement across early childhood. Those are almost exactly the first tasks in the IACC proposal: a common case definition, harmonized phenotyping, prospective longitudinal cohorts, serial biospecimens, and repeated assessment before, during, and after developmental change whenever possible.
The plan also incorporates the methodological warning Science presents as grounds for suspicion. Page 61 says studies “should not depend strictly on retrospective parental recall” and directs investigators to combine medical records, geospatial data, prospectively collected specimens, validated or recorded exposure measures, and prespecified causal-inference methods. Ozonoff’s study of parent recall found low agreement between reports made when children were two to three years old and reports made when they were about six. One quarter of families changed onset categories, most often because parents later failed to remember a regression they had reported earlier. That finding warns against retrospective timing estimates without making regression imaginary or justifying the dismissal of skill loss reported closer to the event; it supports prospective observation, which is precisely what the plan proposes.
The draft contains mechanistic hypotheses that deserve close review, including immune, mitochondrial, metabolic, purinergic, genetic, gastrointestinal, epileptiform, and environmental pathways. Some are mature enough for structured testing; others remain speculative. The proper scientific response is to classify each by evidence stage, define the subgroup, prespecify the endpoint, and stop failed hypotheses, a discipline the plan repeatedly states. Critics can still argue that particular claims outrun their citations or that some proposed allocations are poorly weighted, but they must examine the claims and citations. Treating the very existence of environmental and immune research as a coded vaccine statement avoids the scientific argument.
The sentence that debunks the article
The most consequential reporting error appears in Reardon’s treatment of developmental timing. She writes that measurable declines “primarily happen within the first 12 months of life” and that this is “earlier than most children receive routine vaccines,” although the first clause is not what her linked source says and the second is incompatible with the schedule.
The linked review by Sally Ozonoff and Ana-Maria Iosif summarizes prospective infant-sibling studies. It reports largely intact early development followed by declines and symptom emergence “around the first birthday and in the second year of life.” It describes groups that look similar at six months, diverge by 12 months, and continue to diverge afterward. A statistically detectable group difference at 12 months does not mean that the underlying declines occurred primarily before 12 months, much less that they were complete by then. The review’s own summary states that decline occurs during the first and second years of life. Tan and colleagues’ 19.8-month weighted mean provides an independent check against Reardon’s compressed chronology.
The vaccination claim fails by ordinary calendar comparison. The CDC’s January 2026 framework retained vaccines for pertussis, tetanus, diphtheria, Hib, pneumococcal disease, and polio in the category recommended for all children. The agency’s posted age table places the first DTaP, Hib, pneumococcal, and polio doses at two months, followed by doses at four and six months. Whatever causal question one wishes to investigate, routine childhood vaccination plainly begins before the first birthday and long before the 19.8-month mean reported in the meta-analysis. Calendar arithmetic and source fidelity settle this narrow point without deciding any causal question about vaccines.
This is where the article debunks itself most cleanly. It links a paper that places decline across the first and second years, converts the emergence of group differences by 12 months into a claim that decline primarily occurs within 12 months, and then places routine vaccination later than a schedule that starts in infancy. The resulting sentence is not a cautious summary of unsettled science. It is a timeframe substitution followed by a factual error about vaccine timing.
The rollout’s critiques have their say, and Science still misstated it
The committee’s process evidently gives critics some material. They claim a A 336-page plan should not be placed on an abbreviated review track, that thousands of public comments should not reach voting members less than a day before deliberation, and that a member who requested disability accommodation should receive time and access sufficient to participate. They do like that drafters lacked a complete institutional record and formal handoff, did not have the unreleased 2024 strategic plan, and relied on public materials they could independently locate. They do not like that Appendix A says one portfolio classification used a language-model classifier applying fixed rules, with only approximate reproducibility and without careful human review of every project. They say these are material limits because they affect continuity, agency verification, cost assumptions, and the reliability of the portfolio categories used to justify priorities.
One has to wonder if other U.S. agency committees are held to the same standard, and more on point, where these critics were during the long tenure of “speak-no-harm” Advisory Committee on Immunization Practices (ACIP) where the word “risk” was, evidently, banned speech if associated with vaccines.
Still, after 26 years of the IACC predecessor committees existing and doing virtually nothing about environmental factors that have been associated with autism, one has to acknowledge that this IACC has a lot to make up for.
Given the criticisms, Science had a strong process story available but weakened it with another chronology error. Reardon says IACC released the July draft four days before its next public meeting. The Federal Register notice scheduled the meeting for July 31. Contemporary reporting says the draft was released on Monday, July 20, which made the interval eleven days. Four days was the original public-comment period, as Disability Scoop reported on July 23. The distinction does not rescue the committee’s process; four days for public comment on 336 pages was indefensible. It does show that Science converted a valid criticism into an inaccurate sentence.
The August process remained compressed: thirteen autism organizations asked the committee to delay the vote until members could review the public input, federal members abstained in large numbers, and Scott Robertson stated that he could not process the material on the schedule provided. Those facts support criticism of governance and accessibility. They do not prove that a $57 million multi-pathway regression initiative is a secret vaccine project.
But even that logic defiles the prima facie reality recognized by anyone who bothers to examine the history of studies proferred as definitive on the question: Bona fide, good-faith studies of the role of vaccines in autism etiology are long overdue.
The burden Science never met
Committee membership matters because people choose priorities, interpret evidence, and control agendas, and Kennedy’s history makes vigilance warranted. A member’s financial or organizational ties can create conflicts that should be disclosed and managed. These propositions establish a reason to inspect the plan closely without determining what inspection must find. Reardon’s article reverses that sequence by beginning with the people, treating regression and environmental research as suspicious because of those people, and then using the absence of vaccine language as evidence that the agenda is veiled. This makes the claim resistant to disproof: explicit vaccine language would prove the agenda, while no vaccine language proves concealment. A claim structured that way cannot be audited and can only be believed or rejected.
An auditable approach begins by identifying the operative language, the funded exposure, the protocol, the endpoint, the agency instruction, and the causal presumption. If a later NIH solicitation turns “environmental exposures” into a vaccine study, the solicitation can be read and criticized on its terms. But why shouldn’t they? If CDC adopts a regression definition built around vaccination, that definition will be evidence - of something. If an agency steers money outside the plan’s stated exposure categories, the award record will show it. The August working draft contains none of those acts.
But we hope NIH funds vaccine studies to the hilt.
Science promised readers a veiled antivaccine focus. The document shows a broad autism research and services plan with an explicit, minority allocation for regression; the plan’s methods answer the caution urged by the experts Science quotes; the linked regression review contradicts the article’s 12-month formulation; and the federal immunization schedule contradicts its vaccine-timing claim. The committee’s rushed process merits direct criticism, and parts of the draft warrant stringent scientific review, but the hidden vaccine case still requires evidence. Reardon’s article did not produce it because the sources she cited support the regression research question and defeat the sentence used to make that question look suspect. That is how Science debunked its own framing of the IACC plan.
Source record
1. Sara Reardon, “In autism advisory committee’s funding plan, critics see a veiled antivaccine focus,” Science, August 31, 2026.
2. Interagency Autism Coordinating Committee, August 27, 2026 meeting materials.
3. Interagency Autism Coordinating Committee, Updated IACC Working Draft Strategic Plan 2026–2028, August 17, 2026, especially pp. 26–29, 56–61, 68–70, 90–92, 255–260.
4. Sally Ozonoff and Ana-Maria Iosif, “Changing Conceptualizations of Regression: What Prospective Studies Reveal About the Onset of Autism Spectrum Disorder,” Neuroscience & Biobehavioral Reviews 100 (2019): 296–304. doi:10.1016/j.neubiorev.2019.03.012.
5. Christine Tan et al., “Prevalence and Age of Onset of Regression in Children with Autism Spectrum Disorder: A Systematic Review and Meta-analytical Update,” Autism Research 14, no. 3 (2021): 582–598. doi:10.1002/aur.2463.
6. Sally Ozonoff et al., “Reliability of Parent Recall of ASD Symptom Onset and Timing,” Autism 22, no. 8 (2018): 891–896. doi:10.1177/1362361317710798.
7. Centers for Disease Control and Prevention, “CDC Acts on Presidential Memorandum to Update Childhood Immunization Schedule,” January 5, 2026; and “Recommended Vaccines for Young Children,” childhood schedule by age.
8. U.S. Department of Health and Human Services, “Office of the Secretary; Notice of Meeting,” Federal Register, July 7, 2026.
9. Michelle Diament, “After Uproar, Feds Back Off Rushed Effort To Approve New Autism Plan,” Disability Scoop, July 23, 2026.
10. Autistic Self Advocacy Network, “Community Calls on IACC to Review All Public Input Before Strategic Plan Vote,” August 26, 2026.
11. U.S. Food and Drug Administration, “FDA Approves First Treatment for Patients with Cerebral Folate Transport Deficiency,” March 10, 2026.
Let me say in plain English. I don't give a flying fuck what Alison Singer has to say.
Huh? Regression is a statisticalmethod to determine how one variable affect another. https://www.investopedia.com/terms/r/regression.asp Confusing!